Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.
Eligible age
18–70 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Most patients with mCRC are treated with palliative chemotherapy and only a small number of patients with limited metastatic disease achieve long-term remission following metastasectomy. There is a growing need for more effective treatment in patients with liver-only mCRC to improve the rate of curative resection without compromising QOL.The current study is informed by our patient's needs. It aims to evaluate the rate of conversion therapy in patients with unresectable liver-only mCRC using the combination of FOLFOXIRI and bevacizumab and to assess the association between an early FDG-PT/CT response and other clinical and pathological biomarkers and hepatic metastasectomy.
Sponsor: University of Saskatchewan
You may qualify if…
- ✓ Adult patients, aged between 18 and 70 years with histologically proven adenocarcinoma or poorly differentiated carcinoma of the colon and rectum with unresectable liver-only metastases and no extra-hepatic disease.
- ✓ World Health Organization (WHO) performance status of 0-1.
- ✓ No previous chemotherapy for advanced disease.
- ✓ Adequate functioning of the bone marrow, liver, and kidneys.
You may not qualify if…
- ✕ Breastfeeding or pregnancy.
- ✕ An active second primary cancer with the exception of squamous cell carcinoma of the skin or an in situ cancer.
- ✕ Severe or uncompensated concomitant medical conditions.
Source: ClinicalTrials.gov · NCT03401294 · last updated 2025-05-09